Article
Oncology
Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kalamacki, Dorota Kiprian, Tomasz Banas
Summary: Epithelial ovarian cancer is the deadliest gynaecological malignancy, and cytoreductive surgery followed by adjuvant taxane-platinum-based chemotherapy is the main therapy for this cancer. Systemic inflammatory response plays a dual role in the pathophysiology of neoplastic diseases, predicting poor survival. However, there are only few studies on changes in inflammatory markers during anti-cancer treatment. This study aimed to investigate trends in changes in inflammatory markers in women with ovarian cancer receiving standard first-line adjuvant chemotherapy.
Article
Reproductive Biology
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi, Yaqing Chen
Summary: This study evaluated the efficacy and safety of PLD in treating platinum-resistant and platinum-refractory relapse in patients with epithelial ovarian, fallopian tube, and peritoneal cancer. The results showed that PLD was associated with satisfactory efficacy, low frequency of adverse events, and high patient quality of life, with low baseline CA125 levels and a reduction in CA125 after the first cycle predicting satisfactory efficacy.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Medicine, Research & Experimental
Dilys Leung, Zoe K. Price, Noor A. Lokman, Wanqi Wang, Lizamarie Goonetilleke, Elif Kadife, Martin K. Oehler, Carmela Ricciardelli, George Kannourakis, Nuzhat Ahmed
Summary: The study identified novel EMT-related markers in platinum-resistant ovarian cancer cells, indicating a potential link between EMT and chemotherapy resistance. Proteomic analysis revealed enhanced cell migration and reduced proliferation, glycolysis, and oxidative phosphorylation in resistant cell lines.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Roberta Affatato, Michela Chiappa, Federica Guffanti, Francesca Ricci, Laura Formenti, Robert Fruscio, Marta Jaconi, Maya Ridinger, Mark Erlander, Giovanna Damia
Summary: In a patient-derived xenograft model of platinum-resistant ovarian carcinoma, the combination of paclitaxel and onvansertib showed good tolerability and significantly inhibited tumor growth, resulting in extended survival in mice. Ex vivo experiments also demonstrated increased apoptosis and DNA damage in tumor cells treated with the combination.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Claudia Marchetti, Francesca De Felice, Alessia Romito, Valentina Iacobelli, Carolina Maria Sassu, Giacomo Corrado, Caterina Ricci, Giovanni Scambia, Anna Fagotti
Summary: Ovarian cancer is a fatal malignancy with most patients experiencing recurrent and chemotherapy-resistant disease. Understanding the complexity of platinum-resistant OC, identifying reliable biomarkers, and developing innovative therapies are crucial in improving management. Efforts to overcome platinum resistance in OC represent a dynamic field with rapidly developing drugs and clinical trials.
SEMINARS IN CANCER BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Giovanni Tossetta
Summary: Ovarian cancer is a highly dangerous gynecologic cancer with a high fatality rate and recurrence. Chemoresistance greatly reduces the effectiveness of paclitaxel and platinum-based drugs used for treatment. Metformin, commonly used for diabetes and fatty liver disease, shows anti-tumor activity and reduces cancer risk and chemoresistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
L. R. Duska, C. N. Krasner, D. M. O'Malley, J. L. Hays, S. C. Modesitt, C. A. Mathews, K. N. Moore, P. H. Thaker, A. Miller, C. Purdy, W. C. Zamboni, A. T. Lucas, J. G. Supko, R. J. Schilder
Summary: EP0057, an investigational nanoparticle-drug conjugate, in combination with paclitaxel has shown efficacy in treating recurrent EOC, with a recommended phase 2 dose of 15 mg/m(2) EP0057 every 2 weeks plus 80 mg/m(2) paclitaxel weekly. Although the observed overall response rate was not statistically better than historical control rate, EP0057 remains an interesting option for treatment of recurrent EOC.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Adel Alblihy, Muslim L. Alabdullah, Reem Ali, Mashael Algethami, Michael S. Toss, Nigel P. Mongan, Emad A. Rakha, Srinivasan Madhusudan
Summary: Platinum resistance in ovarian cancer patients is strongly associated with nuclear NBS1 overexpression, which impacts progression free survival (PFS) and overall survival (OS). NBS1 mRNA overexpression is also linked to poor PFS outcomes. Preclinically, nuclear localization of NBS1 in platinum resistant cells was observed, and depletion of NBS1 increased cisplatin cytotoxicity through accumulation of double strand breaks (DSBs), S-phase cell cycle arrest, and increased apoptosis. NBS1 may be a useful predictor for platinum sensitivity in ovarian cancer therapy.
Article
Oncology
Lanbo Zhao, Sijia Ma, Linconghua Wang, Yiran Wang, Xue Feng, Dongxin Liang, Lu Han, Min Li, Qiling Li
Summary: By analyzing hundreds of samples, this study identified key genes associated with chemotherapy resistance and established a polygenic methylation prediction model with 29 core genes related to chemotherapy resistance. The methylation levels of these key genes showed a negative correlation with mRNA expressions and potential prognostic significance.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Endocrinology & Metabolism
Laura J. Reid, Fraser W. Gibb, Helen Colhoun, Sarah H. Wild, Mark W. J. Strachan, Karen Madill, Baljean Dhillon, Shareen Forbes
Summary: This study compared the progression of diabetic retinopathy in patients with type 1 diabetes who received CSII therapy versus MDI therapy. The results showed that CSII therapy was associated with reduced progression of diabetic retinopathy compared to continued MDI therapy, especially for patients with high baseline HbA(1c). The progression of retinopathy over 3 years was not affected by changes in HbA(1c).
Article
Chemistry, Medicinal
Qingli Cui, Yanhui Hu, Dongyang Ma, Huaimin Liu
Summary: Anlotinib showed moderate improvements in progression-free survival and overall survival in patients with platinum-resistant or platinum-refractory ovarian cancer, indicating it may be a new treatment option for this group of patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Hongqin Zhang, Tianqing Yan, Ailing Zhong, Lin Guo, Renquan Lu
Summary: The upregulation of COPS5 is associated with platinum resistance in epithelial ovarian cancer (EOC), and its overexpression is correlated with shorter survival. Inhibition of COPS5 reduces EOC cell proliferation, migration, and sensitivity to platinum.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2022)
Article
Reproductive Biology
Sipei Nie, Yicong Wan, Hui Wang, Jinhui Liu, Jing Yang, Rui Sun, Huangyang Meng, Xiaolin Ma, Yi Jiang, Wenjun Cheng
Summary: This study identified the important role of CXCL2 in platinum resistance in epithelial ovarian cancer, providing a novel target for chemoresistance prevention. The results showed that CXCL2 up-regulation promoted cell resistance to cisplatin and maintained cell stemness through activating the ATR/CHK1 signaling pathway in EOC. Additionally, the resistance mediated by CXCL2 could be reversed by specific inhibitors, offering potential therapeutic strategies for overcoming chemotherapy resistance in EOC.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Makio Shozu
Summary: The study evaluated the safety and efficacy of weekly paclitaxel and cisplatin chemotherapy in patients with ovarian cancer who developed carboplatin hypersensitivity reaction. The majority of patients were able to complete the treatment without hypersensitivity reactions, and the therapy was found to be well-tolerated and effective for most patients.
Article
Medicine, Research & Experimental
Xin Wu, Ling Qiu, Hao Feng, Hao Zhang, Hailin Yu, Yan Du, Hao Wu, Shurong Zhu, Yuanyuan Ruan, Hua Jiang
Summary: This study investigates the role of KHDRBS3 in glycolysis and increased resistance to Paclitaxel (PTX) in epithelial ovarian cancer (EOC). The results reveal a KHDRBS3-MIR17HG-CLDN6 regulatory axis that contributes to enhanced glycolysis in EOC and represents a potential target for therapy.